Comprehensive Overview of GLP-1 RAs in Cardiometabolic Care

The not-so-sudden rise of weight loss ”wonder” drugs for T2D and obesity This World Obesity Day, March 4, 2024, weight loss drugs dominate discussions and raise new questions for clinicians. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have been used to treat type 2 diabetes (T2D) since the approval of Byetta (exenatide) in 2005. In the […]

GLP-1 Receptor Agonist Lixisenatide Approved by US FDA

The GLP-1 receptor agonist lixisenatide has received US FDA approval for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. Approval was based on 11 clinical trials that evaluated more than 11,000 patients, including a cardiovascular outcomes trial, ELIXA, that showed no increase in adverse cardiovascular events. Efficacy studies […]


Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.